“Working at Wave for the past 5 years has really opened my eyes to the medical field and the importance of what we are striving to do. Wave is by far one of the most diverse, family-oriented companies I have ever worked for. With my role in Supply Chain Logistics, I am fortunate to play a hand in many departments and there is no better atmosphere than here at Wave.”
Wave Life Sciences
バイオテクノロジー研究
Cambridge、Massachusetts18,236人のフォロワー
Unlocking the broad potential of RNA medicines to transform human health
Our team includes some of the world’s most respected oligonucleotide chemists, drug development experts and dedicated patient advocates.
-
Paul Bolno
President and CEO at Wave Life Sciences
-
Chandra Vargeese
Chief Technology Officer and Head of Platform Discovery Sciences at Wave Life Sciences
-
Anne-Marie Li-Kwai-Cheung
20+ years trying to find solutions for people with neurological and rare diseases
-
Chris Francis
SVP, Corporate Development & Head of Emerging Areas at Wave Life Sciences
Driven to Reimagine Possible
At Wave, we are focused on unlocking the broad potential of RNA medicines to transform human health. To do this, we are leveraging a toolkit of RNA-targeting modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Join us, and together we’ll reimagine what’s possible for medicine and for patients.
Learn about career opportunities at WaveCorporate Sustainability at Wave
Delivering on our vision requires a focus on our values and corporate sustainability, including environmental, social and governance (ESG) initiatives with strong focus on Diversity, Equity and Inclusion (DEI), Human Capital (HC), and Patient and Community Engagement.
Read about our corporate sustainability initiativesSpotlight on: RNA Editing
Wave is developing a new way to treat human disease called "RNA editing." Our approach uses short, fully chemically modified oligonucleotides to harness editing enzymes that already exist in the body called "ADAR." In 2023, we became the first company in the world to bring an RNA editing program into clinical development.
Read about Wave's leading RNA editing capability